Drugs / DQ1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07622862 | Jun 2026 → Sep 2027 expected | plasma cell myeloma | Zhongshan Hospital (Xiamen), Fudan University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DQ1001 | “Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)” NCT07622862 ↗ |
| Modality | Cell therapy | “DQ1001-a Universal Allogeneic CAR-T Cell Infusion Targeting Both BCMA and GPRC5D” NCT07622862 ↗ |
| Route | Intravenous | “All participants will receive intravenous infusions of DQ1001” NCT07622862 ↗ |
| Target | GPRC5D | “DQ1001-a Universal Allogeneic CAR-T Cell Infusion Targeting Both BCMA and GPRC5D” NCT07622862 ↗ |